试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-18
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
编号:NCT05720052登记状态:提前终止企业 / 申办者:MingSight Pharmaceuticals, Inc
药物 / 成分:MS-553
登记的停止原因(原文):The study is terminated due to major protocol revisions.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-18
A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
编号:NCT06507891登记状态:提前终止企业 / 申办者:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
药物 / 成分:TQ-A3334 tablets、TQ-A3334 tablets + Anlotinib capsules
登记的停止原因(原文):After considering the company's project situation and strategic development direction, it has been decided to terminate this project. The experiment will be terminated for non safety reasons.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-17
Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors
编号:NCT00684957登记状态:提前终止企业 / 申办者:Columbia University
药物 / 成分:Recombinant Human Growth Hormone、Recombinant Human IGF-1
登记的停止原因(原文):Poor enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-17
Correlation Between NOL Index After Stimulus and Post-operative Opioid, Pain, Pre-operative Phenotype
编号:NCT03422783登记状态:提前终止企业 / 申办者:Ciusss de L'Est de l'Île de Montréal
药物 / 成分:Standardized tetanic stimulation、Catastrophizing score、Nociceptive threshold、Biomarkers
登记的停止原因(原文):Stopped in march 2024 because lead investigator left Canada
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-17
Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
编号:NCT03956056登记状态:提前终止企业 / 申办者:Washington University School of Medicine
药物 / 成分:Neoantigen Peptide Vaccine、Poly ICLC、Blood for immune monitoring
登记的停止原因(原文):Insufficient funding/staff
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-17
Study Evaluating the Safety and Feasibility of Platelet-rich Plasma to Treat Facetogenic Low Back Pain
编号:NCT05250947登记状态:提前终止企业 / 申办者:Matthew Pingree
药物 / 成分:Angel® Concentrated Platelet Rich Plasma System、Platelet Rich Plasma
登记的停止原因(原文):Projected cost to continue was not supported by the study budget and additional funds could not be obtained so the decision to close the study was made.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-16
Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.
编号:NCT03500484登记状态:提前终止企业 / 申办者:Yale University
药物 / 成分:Liraglutide
登记的停止原因(原文):The study was initially paused due to COVID restrictions and then when able to resume, there was no longer funding.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-16
Efficacy of Platelet Enriched Plasma in Preventing Surgery for Patients With Chronic Tympanic Membrane Perforation
编号:NCT03837665登记状态:提前终止企业 / 申办者:University of Kansas Medical Center
药物 / 成分:Platelet Rich Plasma
登记的停止原因(原文):Recruitment barriers
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-16
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
编号:NCT04159896登记状态:提前终止企业 / 申办者:Barbara Ann Karmanos Cancer Institute
药物 / 成分:Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981、Nivolumab
登记的停止原因(原文):The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA events.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-16
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis
编号:NCT04853368登记状态:提前终止企业 / 申办者:AbbVie
药物 / 成分:ABBV-576、Galicaftor、Placebo、Navocaftor
登记的停止原因(原文):Strategic considerations
查看官方原始记录 ↗